Roche Sales Growth Continues in Q3 2024
Group sales for Roche displayed remarkable resilience, growing by 6% at constant exchange rates (CER) in the first nine months of the year. Notably, the robust performance was fueled by high demand for both medicines and diagnostics, with sales, excluding COVID-19-related products, increasing by 8%. In the third quarter, group sales rose by 9% (6% in CHF), maintaining a consistent growth pattern that was evident in previous quarters.
Pharmaceuticals Division Performance
The Pharmaceuticals Division reported a 7% sales increase in the first nine months, with a strong base business growth of 9%. This surge was predominantly driven by sustained demand for new treatments targeting severe diseases. Key growth contributors included Vabysmo, aimed at treating serious eye conditions, Phesgo for breast cancer, and Ocrevus for multiple sclerosis.
Diagnostics Division Contributions
Sales in the Diagnostics Division increased by 5% during the same period, with an 8% rise in the base business. This performance was propelled by heightened demand for immunodiagnostic products, pathology solutions, and molecular diagnostics, showcasing the vital role these segments play within Roche's broader portfolio.
Recent Regulatory Approvals
Roche achieved significant milestones with several recent regulatory approvals. Among the highlights was the approval of Itovebi (inavolisib) for advanced breast cancer, which has shown promising efficacy in clinical trials. Additionally, Ocrevus Zunovo received FDA approval as the first subcutaneous injection for multiple sclerosis, potentially transforming treatment access for many patients.
Expansion and Innovation in Diagnostics
The launch of the cobas Respiratory flex test marks another innovation in Roche's diagnostics offerings. This test leverages new Temperature-Activated Generation of Signal (TAGS) technology, enabling simultaneous detection of multiple respiratory viruses, which could revolutionize diagnostics in this area.
Sales Summary and Outlook
As of the first nine months of 2024, Roche reported Group sales of CHF 45.0 billion, reflecting the strong uptake of their novel medicines and diagnostic products. The company now anticipates an increase in Group sales in the mid-single-digit range for 2024, with core earnings projected to grow in the high single digits.
Continued Commitment to Innovation
Roche has reaffirmed its commitment to sustainability and innovation. The company plans to increase its dividend in Swiss francs while continuing to invest in research and development, focusing on personalized healthcare solutions that aim to improve patient outcomes worldwide.
Achievements in Key Markets
In various regions, sales growth has been encouraging. In the United States, increased sales of Vabysmo and Ocrevus have helped offset declines in other areas due to patent expirations. Meanwhile, notable sales growth has been recorded in the International and European markets, emphasizing Roche’s strong global presence.
Frequently Asked Questions
What was Roche's sales growth in Q3 2024?
Roche reported a 6% sales growth at constant exchange rates in Q3 2024.
What contributed to the growth in the Pharmaceuticals Division?
The growth in the Pharmaceuticals Division was driven by high demand for innovative treatments such as Vabysmo, Phesgo, and Ocrevus.
What new products did Roche launch recently?
Roche launched the cobas Respiratory flex test, utilizing new TAGS technology to detect multiple viruses simultaneously.
What is Roche's outlook for 2024?
Roche expects to increase Group sales in the mid-single-digit range and core earnings in the high single-digit range for 2024.
How is Roche contributing to sustainability?
Roche is committed to achieving net zero by 2045 and continues to integrate sustainability into its business operations.
